Ultragenyx Reports Positive Phase 3 Data for DTX301 Gene Therapy in OTC Deficiency
Summary
Ultragenyx announced positive Phase 3 results for its DTX301 gene therapy for OTC deficiency, demonstrating significant ammonia reduction and improved patient outcomes with an acceptable safety profile.
Key Events
-
Positive Phase 3 DTX301 Results
The Enh3ance study showed DTX301 gene therapy achieved a statistically significant 18% reduction in 24-hour plasma ammonia (p=0.018) compared to placebo at Week 36 for OTC deficiency.
-
Clinically Meaningful Patient Benefits
Treated patients maintained normal ammonia levels, reduced ammonia scavenger medications by 27%, and increased protein intake by 13%. Patient global impression scale (PGIC) showed 71% of treated patients were much improved.
-
Favorable Safety Profile
DTX301 was well tolerated, with mild to moderate transient hepatic reactions as the most common adverse events. The treated group experienced significantly fewer hyperammonemic crises and no deaths compared to placebo.
-
Pipeline Boost After Recent Setbacks
This positive data for DTX301 provides a significant boost to Ultragenyx's pipeline, following recent disclosures in the 10-K regarding the failure of the UX143 study and an Incomplete Response Letter for UX111.
Analysis
This 8-K announces highly positive Phase 3 results for DTX301, a gene therapy for ornithine transcarbamylase (OTC) deficiency. The data shows a statistically significant reduction in plasma ammonia, maintenance of normal ammonia levels, and significant patient-reported improvements in symptoms. Importantly, treated patients reduced their reliance on scavenger medications and increased protein intake, indicating a meaningful clinical benefit. The safety profile was acceptable, with fewer hyperammonemic crises in the treated group compared to placebo. This positive development is particularly impactful following recent setbacks for other pipeline assets, as disclosed in the company's last 10-K, and provides a strong positive signal for the company's gene therapy platform.
At the time of this filing, RARE was trading at $21.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $18.41 to $42.37. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.